DN
Durga Naveen Vannemreddy
About Durga Naveen Vannemreddy
Durga Naveen Vannemreddy has 5 years in corporate governance. Holds Director and Designated Partner roles. Currently with 3 companies, including Harikrishna Institute Of Oncology Private Limited and De Vita Bio Life Sciences Llp. Formerly with 1 company. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
De Vita Bio Life Sciences Llp
AAH-7949
|
Designated Partner | 08 Oct 2022 | 2016 | Active |
Surat Institute Of Oncology Private Limited
U86100GJ2024PTC156200
|
Director | 06 Nov 2024 | 2024 | Active |
Lifelan Digital Private Limited
U63999KA2024PTC186629
|
Director | 23 Mar 2024 | 2024 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Harikrishna Institute Of Oncology Private Limited
U85190TG2020PTC144475
|
Director | 03 Oct 2020 | 2020 | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Durga Naveen Vannemreddy
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Durga Naveen Vannemreddy
Durga Naveen Vannemreddy has 5 years in corporate governance. Holds Director and Designated Partner roles. Currently with 3 companies, including Harikrishna Institute Of Oncology Private Limited and De Vita Bio Life Sciences Llp. Formerly with 1 company. Engaged in General Business. Contributes to corporate operations.
Durga Naveen Vannemreddy is associated with 3 companies as Director and Designated Partner.
Durga Naveen Vannemreddy has expertise in General Business.
Durga Naveen Vannemreddy has 5 years in corporate governance.